Oslo, 26 August 2022, Lytix Biopharma AS, has today been notified that the following transaction has been completed by a primary insider in Lytix Biopharma AS: Øystein Rekdal, CEO and primary insider in Lytix Biopharma AS, has today bought 13,000 shares at an average price of NOK 7.7274 per share. After the transaction, Øystein Rekdal holds 139,963 shares in Lytix Biopharma AS. 

Please refer to the attached notification of trading for further details. 

This information is subject to the disclosure requirements in the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act. 

For further information, please contact: Gjest Breistein, CFO, gjest.breistein@lytixbiopharma.no, +47 9526 0512